CN105343520A - Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases - Google Patents
Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases Download PDFInfo
- Publication number
- CN105343520A CN105343520A CN201510848584.2A CN201510848584A CN105343520A CN 105343520 A CN105343520 A CN 105343520A CN 201510848584 A CN201510848584 A CN 201510848584A CN 105343520 A CN105343520 A CN 105343520A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- herba
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases. The composition is prepared from rhizoma curculiginis, pseudo-ginseng, erigeron breviscapus, polygonum multiflorum, radix puerariae, rheum officinale, loranthus parasiticus, pericarpium citri reticulatae viride, coptis chinensis, flos carthami , radix rehmanniae preparata, herba epimedii, ginseng, dandelion, herba epimedii, ligusticum wallichii, oriental wormwood, angelica sinensis, radix achyranthis bidentatae, asparagus fern, astragalus membranaceus, medicated leaven, schisandra chinensis, salvia miltiorrhiza, pericarpium citri reticulatae, red rhodobryum, morinda officinalis, rhizoma polygonati, semen cuscutae, rhizoma acori graminei and snake gourd fruit shells. The traditional Chinese medicine composition has an extremely good treatment effect on cardiovascular and cerebrovascular diseases, and is ideal medicine for treating cardiovascular and cerebrovascular diseases at present.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease.
Background technology
Cardiovascular and cerebrovascular disease has become the main disease threatening human health and life.The data display of ministry of Health of China announcement in 2005: cardiovascular and cerebrovascular disease is the disease that China's M & M is the highest, and annual patient is up to 100,016,000 people, and nearly 2,600,000 people die from cardiovascular and cerebrovascular disease every year.And morbidity crowd has rejuvenation (35-55 year) trend.In the preventing and treating of cardiovascular and cerebrovascular disease, be applied to clinical although ester medicine, anti-platelet agent and Thrombolytic agent fall in the interventional therapy of modern medicine, surgical operation, statin, but curative effect is not ideal enough, just reach the temporary curative effect that blood vessel dilating improves circulation, too large effect is not had to dissolving of come off speckle or the thrombosis etc. that flow in blood vessel, is difficult to thrombolytic; And often use this type of Western medicine easily to cause arterial blood tube wall flexibility decrease, fragility increases, cerebral infarction is caused progressively to be converted into cerebral hemorrhage serious attack again, cause more large-area infraction, be difficult to cure, and there will be untoward reaction after small number of patients use, side effect is comparatively large, and clinical cure rate is undesirable.Therefore, the medicine of current Cardiovarscular still Shortcomings.
Summary of the invention
The object of this invention is to provide a kind of Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease.
In order to realize object of the present invention, the invention provides a kind of Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease, it comprises the material of following weight portion: Rhizoma Curculiginis 10-15 part, Radix Notoginseng 10-15 part, Herba Erigerontis 9-15 part, Radix Polygoni Multiflori 15-20 part, Radix Puerariae 15-25 part, Radix Et Rhizoma Rhei 20-50 part, Herba Taxilli 15-25 part, Pericarpium Citri Reticulatae Viride 6-10 part, Rhizoma Coptidis 3-9 part, Flos Carthami 15-25 part, Radix Rehmanniae Preparata 12-20 part, Herba Epimedii 6-15 part, Radix Ginseng 10-25 part, Herba Taraxaci 10-25 part, Herba Epimedii 12-20 part, Rhizoma Chuanxiong 10-15 part, Herba Artemisiae Scopariae 15-30 part, Radix Angelicae Sinensis 15-25 part, Radix Achyranthis Bidentatae 9-20 part, Radix Asparagi 10-15 part, Radix Astragali 30-60 part, Massa Medicata Fermentata 6-12 part, Fructus Schisandrae Chinensis 9-15 part, Radix Salviae Miltiorrhizae 9-15 part, Pericarpium Citri Reticulatae 10-18 part, Rhodobryum roseum Limpr. 9-15 part, Radix Morindae Officinalis 9-18 part, Rhizoma Polygonati 15-30 part, Semen Cuscutae 15-30 part, Rhizoma Acori Graminei 9-15 part and Fructus Trichosanthis shell 10-15 part.
Preferably, the Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease of the present invention comprises the material of following weight portion: Rhizoma Curculiginis 12 parts, Radix Notoginseng 12 parts, Herba Erigerontis 10 parts, Radix Polygoni Multiflori 18 parts, Radix Puerariae 20 parts, Radix Et Rhizoma Rhei 30 parts, Herba Taxilli 20 parts, 8 parts, Pericarpium Citri Reticulatae Viride, Rhizoma Coptidis 5 parts, 20 parts, Flos Carthami, 15 parts, Radix Rehmanniae Preparata, Herba Epimedii 10 parts, Radix Ginseng 20 parts, Herba Taraxaci 20 parts, Herba Epimedii 15 parts, Rhizoma Chuanxiong 12 parts, Herba Artemisiae Scopariae 20 parts, Radix Angelicae Sinensis 20 parts, Radix Achyranthis Bidentatae 15 parts, Radix Asparagi 12 parts, the Radix Astragali 50 parts, Massa Medicata Fermentata 10 parts, Fructus Schisandrae Chinensis 10 parts, Radix Salviae Miltiorrhizae 10 parts, Pericarpium Citri Reticulatae 15 parts, Rhodobryum roseum Limpr. 12 parts, Radix Morindae Officinalis 15 parts, Rhizoma Polygonati 20 parts, Semen Cuscutae 25 parts, Rhizoma Acori Graminei 12 parts and Fructus Trichosanthis shell 12 parts.
More preferably, the Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease of the present invention also comprises the material of following weight portion: 2-(4-chloropyridine-2-base imido grpup)-4, the 4-bis-Qiang Jia Ji oxazolidine of 0.03 part.
Most preferably, described Chinese medicine composition can be tablet, dispersible tablet, capsule, pill or decoction.
The present invention also provides the purposes of 2-(4-chloropyridine-2-base imido grpup)-4,4-bis-Qiang Jia Ji oxazolidine in the medicine of preparation treatment cardiovascular and cerebrovascular disease, blood fat reducing.
Preferably, described medicine can be tablet, dispersible tablet, capsule, pill or decoction.
Chinese medicine composition of the present invention has fabulous therapeutical effect to Patients with Cardiovascular/Cerebrovascular Diseases, is be treat the ideal medicine of cardiovascular and cerebrovascular disease at present.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Unless otherwise stated, the percent in the present invention is percetage by weight.
Embodiment
Take Rhizoma Curculiginis 12 grams, Radix Notoginseng 12 grams, Herba Erigerontis 10 grams, Radix Polygoni Multiflori 18 grams, Radix Puerariae 20 grams, Radix Et Rhizoma Rhei 30 grams, Herba Taxilli 20 grams, 8 grams, Pericarpium Citri Reticulatae Viride, Rhizoma Coptidis 5 grams, 20 grams, Flos Carthami, 15 grams, Radix Rehmanniae Preparata, Herba Epimedii 10 grams, Radix Ginseng 20 grams, Herba Taraxaci 20 grams, Herba Epimedii 15 grams, Rhizoma Chuanxiong 12 grams, Herba Artemisiae Scopariae 20 grams, Radix Angelicae Sinensis 20 grams, Radix Achyranthis Bidentatae 15 grams, Radix Asparagi 12 grams, the Radix Astragali 50 grams, Massa Medicata Fermentata 10 grams, Fructus Schisandrae Chinensis 10 grams, Radix Salviae Miltiorrhizae 10 grams, Pericarpium Citri Reticulatae 15 grams, Rhodobryum roseum Limpr. 12 grams, Radix Morindae Officinalis 15 grams, Rhizoma Polygonati 20 grams, Semen Cuscutae 25 grams, Rhizoma Acori Graminei 12 grams and Fructus Trichosanthis shell 12 grams, pulverize, cross 100 mesh sieves, mix homogeneously obtains powder.
Experimental example
Choose cleaning grade SD rat 180, body weight 180-220g, male and female half and half, after rat adaptability is fed 7 days, tail venous blood sampling, detects blood lipid level, get rid of non-health laboratory animal to the impact of experimental result, and sub-cage rearing after rat being divided into 6 groups at random according to body weight, sex, be respectively normal group, model group, positive drug group, administration group 1, administration group 2 and administration group 3, often organize 30.Except normal group gives normal diet nursing, all the other are respectively organized rat and first give vitamin D
3700000 IU/kg, gavage (normal group gives the normal saline of equal volume) in 3 days, then raise with high lipid food (% by weight): cholesterol 1%, propylthiouracil 0.61%, natrii tauroglycocholas 0.35%, Adeps Sus domestica 5%, normal feedstuff 93.04%, raises 8 weeks, to cause dyslipidemia animal model.
After modeling the 3rd day starts administration, and each group dosage is as follows: normal group and model group, give normal saline gavage 1mL/100g body weight; Positive drug group, atorvastatin solution 0.09mg/ml, gives gavage 1mL/100g body weight; Administration group 1, the powder 10g of embodiment adds 1000mL normal saline and becomes suspension, gives gavage 1mL/100g body weight; 2-(4-chloropyridine-2-base imido grpup)-4, the 4-bis-Qiang Jia Ji oxazolidine of administration group 2,0.02g, adds 1000mL normal saline and becomes suspension, give gavage 1mL/100g body weight; Administration group 3,2-(4-chloropyridine-2-base imido grpup)-4, the 4-bis-Qiang Jia Ji oxazolidine of powder 5g and 0.01g of embodiment adds 1000mL normal saline and becomes suspension, gives gavage 1mL/100g body weight.1 times/day, successive administration 20d.
The rat 25% urethane 3ml/kg intraperitoneal injection of anesthesia of each group, after 30 minutes, fixed at back respectively by each group of rat, cut abdominal cavity open, abdominal aortic blood 5ml does blood lipids index.The centrifugal 10min of abdominal aortic blood 5ml, centrifuge 5000 turns/min, prepares serum.Aspartate transaminase (AST) activity detection kit (Sigma-Aldrich) is adopted to detect AST.
The results are shown in following table.
| Group | AST(U/L) |
| Normal group | 82.56±8.36 |
| Model group | 271.36±14.26 |
| Positive drug group | 192.45±12.38 |
| Administration group 1 | 230.45±10.08 |
| Administration group 2 | 208.45±11.18 |
| Administration group 3 | 218.48±12.21 |
Compare with normal group, model group and each treatment group AST content all significantly raise; Model group compares, and after treatment, each treatment group AST content obviously declines, and illustrates all have therapeutic effect.
Claims (6)
1. treat the Chinese medicine composition of cardiovascular and cerebrovascular disease for one kind, it is characterized in that, it comprises the material of following weight portion: Rhizoma Curculiginis 10-15 part, Radix Notoginseng 10-15 part, Herba Erigerontis 9-15 part, Radix Polygoni Multiflori 15-20 part, Radix Puerariae 15-25 part, Radix Et Rhizoma Rhei 20-50 part, Herba Taxilli 15-25 part, Pericarpium Citri Reticulatae Viride 6-10 part, Rhizoma Coptidis 3-9 part, Flos Carthami 15-25 part, Radix Rehmanniae Preparata 12-20 part, Herba Epimedii 6-15 part, Radix Ginseng 10-25 part, Herba Taraxaci 10-25 part, Herba Epimedii 12-20 part, Rhizoma Chuanxiong 10-15 part, Herba Artemisiae Scopariae 15-30 part, Radix Angelicae Sinensis 15-25 part, Radix Achyranthis Bidentatae 9-20 part, Radix Asparagi 10-15 part, Radix Astragali 30-60 part, Massa Medicata Fermentata 6-12 part, Fructus Schisandrae Chinensis 9-15 part, Radix Salviae Miltiorrhizae 9-15 part, Pericarpium Citri Reticulatae 10-18 part, Rhodobryum roseum Limpr. 9-15 part, Radix Morindae Officinalis 9-18 part, Rhizoma Polygonati 15-30 part, Semen Cuscutae 15-30 part, Rhizoma Acori Graminei 9-15 part and Fructus Trichosanthis shell 10-15 part.
2. the Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease according to claim 1, it is characterized in that, it comprises the material of following weight portion: Rhizoma Curculiginis 12 parts, Radix Notoginseng 12 parts, Herba Erigerontis 10 parts, Radix Polygoni Multiflori 18 parts, Radix Puerariae 20 parts, Radix Et Rhizoma Rhei 30 parts, Herba Taxilli 20 parts, 8 parts, Pericarpium Citri Reticulatae Viride, Rhizoma Coptidis 5 parts, 20 parts, Flos Carthami, 15 parts, Radix Rehmanniae Preparata, Herba Epimedii 10 parts, Radix Ginseng 20 parts, Herba Taraxaci 20 parts, Herba Epimedii 15 parts, Rhizoma Chuanxiong 12 parts, Herba Artemisiae Scopariae 20 parts, Radix Angelicae Sinensis 20 parts, Radix Achyranthis Bidentatae 15 parts, Radix Asparagi 12 parts, the Radix Astragali 50 parts, Massa Medicata Fermentata 10 parts, Fructus Schisandrae Chinensis 10 parts, Radix Salviae Miltiorrhizae 10 parts, Pericarpium Citri Reticulatae 15 parts, Rhodobryum roseum Limpr. 12 parts, Radix Morindae Officinalis 15 parts, Rhizoma Polygonati 20 parts, Semen Cuscutae 25 parts, Rhizoma Acori Graminei 12 parts and Fructus Trichosanthis shell 12 parts.
3. the Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease according to claim 1 and 2, is characterized in that, it also comprises the material of following weight portion: 2-(4-chloropyridine-2-base imido grpup)-4, the 4-bis-Qiang Jia Ji oxazolidine of 0.03 part.
4. the Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease according to claim 1 and 2, is characterized in that, described Chinese medicine composition can be tablet, dispersible tablet, capsule, pill or decoction.
The purposes of 5.2-(4-chloropyridine-2-base imido grpup)-4,4-bis-Qiang Jia Ji oxazolidine in the medicine of preparation treatment cardiovascular and cerebrovascular disease.
6. purposes according to claim 4, is characterized in that, described medicine can be tablet, dispersible tablet, capsule, pill or decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510848584.2A CN105343520A (en) | 2015-11-29 | 2015-11-29 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510848584.2A CN105343520A (en) | 2015-11-29 | 2015-11-29 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105343520A true CN105343520A (en) | 2016-02-24 |
Family
ID=55319678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510848584.2A Pending CN105343520A (en) | 2015-11-29 | 2015-11-29 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105343520A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106511903A (en) * | 2016-12-15 | 2017-03-22 | 山东中医药大学附属医院 | Composition for assisting diuretic in treating old age hypertension and improving compliance |
| CN111281971A (en) * | 2020-03-13 | 2020-06-16 | 张明洞 | Pharmaceutical composition capable of reducing blood viscosity |
| CN118557657A (en) * | 2024-08-01 | 2024-08-30 | 吉林敖东延边药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating cardiovascular and cerebrovascular diseases |
| CN118557657B (en) * | 2024-08-01 | 2024-10-29 | 吉林敖东延边药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating cardiovascular and cerebrovascular diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1966004A (en) * | 2006-11-21 | 2007-05-23 | 李文杰 | Medicament for treating cerebrovascular and cardiovascular disease and apoplexy sequelae |
| CN103479896A (en) * | 2013-09-30 | 2014-01-01 | 周复礼 | Medicament for treating cerebral thrombosis and preparation method of medicament |
-
2015
- 2015-11-29 CN CN201510848584.2A patent/CN105343520A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1966004A (en) * | 2006-11-21 | 2007-05-23 | 李文杰 | Medicament for treating cerebrovascular and cardiovascular disease and apoplexy sequelae |
| CN103479896A (en) * | 2013-09-30 | 2014-01-01 | 周复礼 | Medicament for treating cerebral thrombosis and preparation method of medicament |
Non-Patent Citations (1)
| Title |
|---|
| 罗军等: "脑脉康对大鼠微循环及血压的影响", 《第一军医大学学报》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106511903A (en) * | 2016-12-15 | 2017-03-22 | 山东中医药大学附属医院 | Composition for assisting diuretic in treating old age hypertension and improving compliance |
| CN111281971A (en) * | 2020-03-13 | 2020-06-16 | 张明洞 | Pharmaceutical composition capable of reducing blood viscosity |
| CN118557657A (en) * | 2024-08-01 | 2024-08-30 | 吉林敖东延边药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating cardiovascular and cerebrovascular diseases |
| CN118557657B (en) * | 2024-08-01 | 2024-10-29 | 吉林敖东延边药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating cardiovascular and cerebrovascular diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102772745B (en) | Chinese medicinal preparation for treating cancer and preparation method thereof | |
| CN102188560A (en) | Traditional Chinese medicine for treating hyperlipidemia | |
| CN102302654B (en) | Medicinal liquor for effectively treating insomnia | |
| CN103768297A (en) | Traditional Chinese medicine for treating hyperlipoidemia | |
| CN102727779B (en) | Pharmaceutical composition for treating ovarian cysts and preparation method thereof | |
| CN103784602A (en) | Traditional Chinese medicine for treating iron-deficiency anemia | |
| CN103495019B (en) | A kind of tranquilizing by nourishing the heart Chinese medicine preparation and preparation method thereof | |
| CN105288565A (en) | Traditional Chinese medicine composition for treating rheumatoid bone diseases | |
| CN105343520A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN101856487A (en) | Chinese medicament for treating insomnia | |
| CN104435678A (en) | Traditional Chinese medicine composition for treating palpitation caused by qi stagnation and blood stasis syndrome | |
| CN103405719A (en) | Medicament for treatment of depression | |
| CN101987167A (en) | Medicine with cathartic function | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN104606514A (en) | Traditional Chinese medicine composition for treating kidney deficiency type tinnitus | |
| CN101491612B (en) | Medicine for treating mammary hyperplasia and early breast cancer | |
| CN103550679A (en) | Traditional Chinese medicine formula for treatment of lithangiuria | |
| CN1322894C (en) | Chinese medicine for treating nipple discharge | |
| CN104587323A (en) | Traditional Chinese medicine composition for treating leucoderma | |
| CN103860914A (en) | Chinese medicine composition for treating epilepsy | |
| CN103860869A (en) | Traditional Chinese medicine for treating gestational hypertension | |
| CN103736011B (en) | Injection care drug of a kind of cholesterol reducing and preparation method thereof | |
| CN103845690A (en) | Medicament for treating geriatric depression | |
| CN102895580B (en) | Pulse invigorating and kidney tonifying medicament | |
| CN105194088A (en) | Traditional Chinese medicine preparation for treating cerebral apoplexy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160224 |
|
| RJ01 | Rejection of invention patent application after publication |